Direct Flow Medical, Inc. a privately held, emerging medical device Company developing a next generation, minimally invasive implant to treat patients with heart valve disease announced today the issuance of its 5th patent on their Percutaneous Aortic Valve (PAV) Technology. The patent (USP# 7,534,259) entitled: “Nonstented Heart Valves with Formed in situ Support” provides further protection for this second generation PAV device.

The Direct Flow Medical PAV System is a non-metallic, expandable cuff, bovine pericardial tissue valve that allows the physician to assess the hemodynamic outcomes prior to final deployment of the device. The unique and easily repositionable “stentless” valve conforms to the native annulus resulting in tight sealing of the valve which minimizes any paravalvular leaks. The reduction of aortic insufficiency is believed to improve clinical status in these high risk patients with significant co-morbidities including coronary heart disease and congestive heart failure.

Related posts

• FDA Panel Recommends Approval of Medtronic Heart Valve under Humanitarian Device Exemption (0)
• CE Mark Clearance for Coherex Medical’s Coherex FlatStent EF PFO Closure System Entirely Anticipated Based on its Performance in Clinical Trial, MDs Say (0)
• 800th Implant of World’s Only Approved Total Artificial Heart Performed by Heart and Diabetes Center NRW (0)
• MiCardia Announces First U.S. Implant (0)
• St. Jude Medical Announces European Approval of Its Newest Heart Failure Devices Which Enable More Efficient Implantation and Follow-up (0)